Abstract: In a well-established many-body framework, successful in modeling a great variety of nuclear processes, we analyze the role of the spectral functions (SFs) accounting for the modifications of the dispersion relation of nucleons embedded in a nuclear medium. We concentrate in processes mostly governed by one-body mechanisms, and study possible approximations to evaluate the particle hole propagator using SFs. We also investigate how to include together SFs and long-range RPA-correlation corrections in the evaluation of nuclear response functions, discussing the existing interplay between both type of nuclear effects. At low energy transfers (<= 50 MeV), we compare our predictions for inclusive muon and radiative pion captures in nuclei, and charge-current (CC) neutrino-nucleus cross sections with experimental results. We also present an analysis of intermediate energy quasi-elastic neutrino scattering for various targets and both neutrino and antineutrino CC driven processes. In all cases, we pay special attention to estimate the uncertainties affecting the theoretical predictions. In particular, we show that errors on the a,,sigma(mu)/sigma(e) ratio are much smaller than 5%, and also much smaller than the size of the SF+RPA nuclear corrections, which produce significant effects, not only in the individual cross sections, but also in their ratio for neutrino energies below 400 MeV. These latter nuclear corrections, beyond Pauli blocking, turn out to be thus essential to achieve a correct theoretical understanding of this ratio of cross sections of interest for appearance neutrino oscillation experiments. We also briefly compare our SF and RPA results to predictions obtained within other representative approaches.

Abstract: We present a compilation and evaluation of experimental beta-delayed neutron emission probabilities (P-n) and half-lives (T-1/2) for known or potential beta-delayed neutron precursors with atomic number Z > 28 (Cu-73 – Fr-233). This article includes the recommended values of both of these quantities, together with a compilation of experimental measurements when available. Some notable cases, as well as proposed standards for beta-delayed neutron measurements are also discussed. Evaluated data has also been compared to systematics using three different approaches. The literature cut-off date for this work is August 15, 2020.

Abstract: Patient Trajectories (PTs) are a method of representing the temporal evolution of patients. They can include information from different sources and be used in socio-medical or clinical domains. PTs have generally been used to generate and study the most common trajectories in, for instance, the development of a disease. On the other hand, healthcare predictive models generally rely on static snapshots of patient information. Only a few works about prediction in healthcare have been found that use PTs, and therefore benefit from their temporal dimension. All of them, however, have used PTs created from single-source information. Therefore, the use of longitudinal multi-scale data to build PTs and use them to obtain predictions about health conditions is yet to be explored. Our hypothesis is that local similarities on small chunks of PTs can identify similar patients concerning their future morbidities. The objectives of this work are (1) to develop a methodology to identify local similarities between PTs before the occurrence of morbidities to predict these on new query individuals; and (2) to validate this methodology on risk prediction of cardiovascular diseases (CVD) occurrence in patients with diabetes. We have proposed a novel formal definition of PTs based on sequences of longitudinal multi-scale data. Moreover, a dynamic programming methodology to identify local alignments on PTs for predicting future morbidities is proposed. Both the proposed methodology for PT definition and the alignment algorithm are generic to be applied on any clinical domain. We validated this solution for predicting CVD in patients with diabetes and we achieved a precision of 0.33, a recall of 0.72 and a specificity of 0.38. Therefore, the proposed solution in the diabetes use case can result of utmost utility to secondary screening.